TargetMol

CCG-1423

Product Code:
 
TAR-T2014
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2014-5mg5mg£96.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2014-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2014-10mg10mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2014-25mg25mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2014-50mg50mg£203.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2014-100mg100mg£291.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2014-200mg200mg£414.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2014-500mg500mg£629.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.
CAS:
285986-88-1
Formula:
C18H13ClF6N2O3
Molecular Weight:
454.75
Pathway:
GPCR/G Protein; Autophagy; Cell Cycle/Checkpoint; MAPK
Purity:
0.9998
SMILES:
CC(ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1
Target:
LRRK2; Rho; Ras

References

1. Evelyn CR, et al. Mol Cancer Ther. 2007, 6(8), 2249-2260. 2. Mae S, et al. Biochem Biophys Res Commun. 2010, 393(4), 877-882. 3. Chong NW, et al. PLoS One. 2012, 7(7), e40966. 4. Johnson LA, et al. Inflamm Bowel Dis. 2014, 20(1), 154-165.